ClinicalTrials.gg
RecruitingNCT05748093OSIBOOST 2Updated Nov 13, 2026

Improving Osimertinib Exposure and Cost-effectiveness Using Pharmacokinetic Boosting With Cobicistat

A Phase 4 interventional study of Cobicistat in Non-small Cell Lung Cancer, sponsored by Maastricht University Medical Center. Recruiting at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-11-13.

Sponsored by Maastricht University Medical Center · Phase 4, Interventional, and Treatment

How we know · 3 judgments

From the registry’s dates

  • Started Apr 2024; still recruiting 2 years 7 months later.
Updated Nov 13, 2026Primary completion movedStudy completion movedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 4
Study type
Interventional
Enrollment
60
Allocation
Non-randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 421 studies in Carcinoma, Non-Small-Cell Lung with a site in Netherlands — 77 open to participants now, 143 under way, 66 of them phase 3. Carcinoma, Non-Small-Cell Lung · Netherlands.

Planned enrollment
296th of 384
60 · median 224
Started
2024
with 29 others
Phase 4
12 of 421
4 open now
Primary completion
2027-07
later than 69 of 142 live
Registered
338th of 421
by date

Among the 421 studies in Carcinoma, Non-Small-Cell Lung with a site in Netherlands, this one is the 296th largest by planned enrollment of the 384 interventional ones that give a count, is one of 30 that started in 2024, is one of 12 in phase 4, reaches primary completion later than 69 of the 142 other live ones, and was the 338th registered.

Carcinoma, Non-Small-Cell Lung

7,639 studies on the registry are indexed under Carcinoma, Non-Small-Cell Lung; 1,838 are open to participants now.

Browse Carcinoma, Non-Small-Cell Lung studies →

Open to participants now

77 of the 421 studies in Carcinoma, Non-Small-Cell Lung with a site in Netherlands are open now. Recruiting first, the newest first:

72 more — sign in →

All 77 open studies →

A study can be open while its sites in Netherlands have not opened yet or have stopped. Only those recruiting at a site in Netherlands →

Who these studies take

Of the 1,324 Carcinoma, Non-Small-Cell Lung studies recruiting now, 987 (75%) set no upper age limit and 225 (17%) stop at 75 or younger; 34 take children under 18; 40 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 421 studies in Carcinoma, Non-Small-Cell Lung with a site in Netherlands, or all of them as a file.
02

Study summary

The goal of this clinical trial is to assess the feasibility of pharmacokinetically boosting osimertinib using cobicistat in order to improve osimertinib exposure in individual patients with advanced NSCLC (Non-Small Cell Lung Cancer) with mutated EGFR (Epidermal Growth Factor Receptor). The main questions it aims to answer are:

  • Cohort 1: Does concurrent use of osimertinib and cobicistat allow for osimertinib weekly intake reductions? If so, how much can the intake be reduced while retaining clinically effective exposure?
  • Cohort 2: Does concurrent use of osimertinib and cobicistat allow for improved penetration of osimertinib in the central nervous system, in patients with CNS (central nervous system) oligoprogression?

Participants who are taking osimertinib in regular care will receive cobicistat in addition to their other medication. They will undergo blood sampling to measure the amount of osimertinib in blood, and measure the effect of boosting. Additionally, in cohort 1 patients will be dose-reduced if their exposure levels allow.

Read the detailed description

In 2016 Osimertinib was registered for the treatment of patients with metastatic Non-Small Cell Lung Cancer (NSCLC) with an activating Epidermal Growth Factor Receptor (EGFR) mutation, initially only for patients with the T790M resistance mutation, but since 2018 also in the first line treatment. Use of osimertinib in the first line provides improved overall survival and progression-free survival, more potent efficacy against brain metastases, and better tolerability compared to older generation EGFR tyrosine kinase inhibitors (EGFR-TKIs). The downside of osimertinib is that -like many new anticancer agents- it is highly expensive (over €70 000 per patient per year in the Netherlands). In a period of five years, healthcare costs associated with expensive medication have risen from €1.71 billion to €2.46 billion per year in the Netherlands. The Dutch Cancer Society has warned that this astronomical cost increase will start to suffocate the national health care budget. In order to safeguard sustained affordability and accessibility of oncological healthcare, improving cost-effectiveness of available drugs is of paramount importance. In a previous study, we have demonstrated that osimertinib exposure may be boosted, through concomitant use of cobicistat, as a result of CYP3A4 inhibition. We now aim to apply pharmacokinetic (PK) boosting in order to improve osimertinib exposure and cost-effectiveness, without impacting treatment efficacy and safety.

This trial is designed to study whether pharmacokinetic boosting may alleviate these issues. In the first cohort, we will assess whether PK-boosting is able to reduce the amount of osimertinib which a patient needs to take. In order to assess this, the patient will receive cobicistat (the booster drug) and we will measure the amount of osimertinib and its metabolite in blood. Afterwards, the researchers and physicians may calculate how much osimertinib a patient actually needs. Ideally this will both reduce the amount of osimertinib that a patient needs to take, as well as reduce the price-tag of the overall treatment. In the second cohort, we will assess whether PK-boosting is a viable alternative to dose-doubling osimertinib. Some patients with NSCLC develop progressive CNS metastases despite osimertinib therapy. There is an indication that increasing the osimertinib dosage to double the standard therapy might provide longer/better treatment efficacy in these patients. Because of the tremendous cost associated with double-dosing osimertinib, most health care insurance providers in the Netherlands do not cover this therapy. In cohort 2 we look to find out whether PK-boosting might provide a similar effect to increasing the dosage, for a far more affordable price-tag.

03

Conditions studied

  • Non-small Cell Lung Cancer

Keywords

  • Osimertinib
  • Cobicistat
  • Pharmacokinetics
  • Boosting
  • Non-small Cell Lung Cancer
  • CNS metastases
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

In order to be eligible to participate in this cohort 1, a subject must meet all of the following criteria:

  • The patient is set to receive osimertinib 80 mg QD as part of their standard treatment plan
  • The patient has a World Health Organization (WHO) Performance Status (PS) of ≤2.
  • The patient is 18 years or older
  • The patient is able and willing to sign
  • The patient is able and willing to undergo blood sampling
  • The patient has non-squamous advanced EGFR-mutated NSCLC with no signs of imminent progression (CT confirmed). If the patient does have signs of progression, they are only eligible if their treating physician deems the treatment to be appropriate beyond progression.
  • The patient consents to their blood being analysed for -genotype

In order to be eligible to participate in this cohort 2, a subject must meet all of the following criteria:

  • The patient is set to receive osimertinib 80 mg QD as part of their standard treatment plan
  • The patient has a World Health Organization (WHO) Performance Status (PS) of ≤2.
  • The patient is 18 years or older
  • The patient is able and willing to sign informed consent
  • The patient is able and willing to undergo blood sampling
  • The patient has non-squamous EGFR-mutated NSCLC with radiologically confirmed progressive ( v1.1), but asymptomatic intracranial , not in an eloquent area (to be discussed with neurologist). Furthermore, the disease is controlled extracranially (no RECIST v1.1 progression).

Exclusion criteria

Exclusion Criteria:

A potential participant who meets any of the following criteria will be excluded from participation in this study:

  • The patient does not take any other drug which is known to strongly inhibit /CYP3A5 activity
  • The patient does not take any other drug which is metabolized by CYP3A4/CYP3A5 and which has a small therapeutic window
  • The patient does not take any drug or product which may otherwise affect CYP3A4/CYP3A5 metabolic activity
  • The patient does not have impaired gastrointestinal function
  • The patient is neither pregnant nor breastfeeding
  • The patient does not have any for cobicistat prescription, as listed in the summary of product characteristics for cobicistat
Terms in these criteria, in plain language(5)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

CYP3A (CYP3A4) inhibitors and inducers

CYP3A is a group of enzymes, mainly CYP3A4, in the liver and gut that break down many medicines. Some medicines, supplements and foods (grapefruit, St John’s wort) slow them down or speed them up, which changes how much of a study drug stays in the body.

Studies list them so they can be avoided or switched; bring a list of everything you take, including supplements.

RECIST

The standard rules for measuring tumors on CT or MRI scans, to tell whether a cancer is shrinking, stable or growing during treatment.

“Measurable disease per RECIST 1.1” usually means at least one tumor 10 mm or more at its longest on a CT scan, or a lymph node 15 mm or more across its short axis.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Phase 4
Primary purpose
Treatment
Allocation
Non-randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
60 participants (estimated)

Study arms

  • Experimental
    Cohort 1: Adjusting osimertinib treatment plans with concomitant pk-boosting

    Feasibility of using pharmacokinetic boosting and TDM to individualize treatment plans and dosage for osimertinib, in patients with advanced NSCLC with mutated EGFR. In this cohort, patients will receive cobicistat for pharmacokinetic boosting of standard osimertinib treatment. Afterwards, they will receive personalised treatment plans, guided by therapeutic drug monitoring.

    Drug: Cobicistat

  • Experimental
    Cohort 2: Improving osimertinib CNS penetration in patients with neurometastases

    Assessing whether pharmacokinetic boosting can improve CNS penetration of osimertinib, in patients with advanced NSCLC with mutated EGFR with asymptomatic CNS oligoprogression. Patients who experience progressive disease intracranially, are sometimes dose-escalated to try and improve osimertinib intracranial exposure. This study will look to demonstrate the feasibility of using a PK-booster instead, potentially providing patients the benefits of higher intracranial treatment efficacy, without needing to take extra osimertinib.

    Drug: Cobicistat

Interventions

  • Feasibility of pharmacokinetic boosting using cobicistat for personalized treatment strategies for osimertinib.

    Also known as: Tybost

This study also gives OsimertinibStudies of OsimertinibOsimertinib pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.. No intervention listed here names it: that was found by reading the record.

06

What researchers measure

Primary outcomes

  1. Cohort 1 primary end-point: Dose modification feasibility

    This cohort aims to demonstrate feasibility and clinical applicability of PK-boosting in the oncological setting. PK-boosting will increase osimertinib availability in plasma. When the availability is increased, a patient will require less osimertinib to achieve the same effect. Therefore, they can be dose-reduced in order to restore them to their normal exposure. In order for this treatment to be considered feasible, the following conditions need to be met: a patient needs to have a stable osimertinib exposure when using the PK-booster, and the patient needs to be dose-modified as a result. The primary endpoint will describe the amount of patients who have: stable exposure; similar to their respective baseline; while using concomitant pk-boosting therapy and a dose modified osimertinib treatment plan; without experiencing significant toxicity. The aim is for this treatment strategy to be considered feasible for at least 75% of patients.

    Time frame: 2-18 months after intervention initiation

  2. Cohort 2 primary end-point: Disease Control Rate at 12 weeks

    This cohort aims to provide improved treatment efficacy in patients with intracranial metastases from NSCLC. Osimertinib penetration in the CNS is much better than that of older generation TKIs, but it is still only 1,49%. Many patients with NSCLC end up developing CNS metastases, a condition known for its dismal prognosis. Currently the only way to increase osimertinib CNS penetration is through dose-escalation: a strategy which causes a tremendous increase in treatment-related toxicity. This cohort looks to improve CNS penetration of osimertinib through the use of a PK-booster (cobicistat). In order to assess treatment efficacy, a MRI will be taken at the start of the trial, and after 12 weeks. A neuro-radiology panel will then assess metastatic response rate. This metastatic response rate will be compared to historical data in order to assess the intracranial treatment efficacy.

    Time frame: 12 weeks after intervention initiation

Secondary outcomes

  1. Cohort 1 secondary end-point: plasma concentrations of osimertinib and AZ5104

    In order to assess the extent of pharmacokinetic boosting in plasma, the plasma concentrations of osimertinib and AZ5104 (metabolite) will be determined.

    Time frame: 2-18 months after intervention initiation

  2. Cohort 1 secondary end-point: safety set

    Number of (serious) adverse events as graded by CTCAE

    Time frame: 2-18 months after intervention initiation

  3. Cohort 1 secondary end-point: Cost-effectiveness analysis

    If in cohort 1 the overall treatment is considered "feasible". An assessment of overall average treatment cost per patient per day will be made for the experimental treatment plan. This will be compared to the current standard treatment cost using a Health-Technology Assessment (HTA). If efficacy endpoints cannot be determined, but the trial treatment is considered "feasible", then the trial treatment will be assessed as "non-inferior" (as the TDM-strategy looks to maintain similar drug exposure).

    Time frame: 2-18 months after intervention initiation

  4. Cohort 1 secondary end-point: CYP3A predictiveness for osimertinib exposure

    Assessing predictiveness of CYP3A-polymorphism for osimertinib exposure. This will be done by statistically comparing osimertinib exposure for patient groups with different genotypes.

    Time frame: 2-18 months after intervention initiation

  5. Cohort 2 secondary end-point: plasma concentrations of osimertinib and AZ5104

    In order to assess the extent of pharmacokinetic boosting in plasma, the plasma concentrations of osimertinib and AZ5104 (metabolite) will be determined.

    Time frame: 12 weeks after intervention initiation

  6. Cohort 2 secondary end-point: safety set

    Number of (serious) adverse events as graded by CTCAE

    Time frame: 12 weeks after intervention initiation

Other outcomes

  1. Cohort 1 exploratory end-point: Comparison of progression-free survival to historical data

    The efficacy of palliative cancer treatment is mostly assessed through progression-free survival. Because of its explorative nature, this trial will not be equipped to provide a statistical analysis of both treatments. Therefore average progression-free survival will be compared numerically to historical data, in order to provide an indication of treatment efficacy.

    Time frame: 2-18 months after intervention initiation

  2. Cohort 2 exploratory end-point: Comparison of Progression-free Survival to historical data

    The efficacy of palliative cancer treatment is mostly assessed through progression-free survival. Because of its explorative nature, this trial will not be equipped to provide a statistical analysis of both treatments. Therefore average progression-free survival will be compared numerically to historical data, in order to provide an indication of treatment efficacy.

    Time frame: 12 weeks after intervention initiation

  3. Cohort 2 exploratory end-point: Extracranial disease control

    Disease control rate for extracranial disease, as assessed by thoracic imaging

    Time frame: 12 weeks after intervention initiation

  4. Cohort 2 exploratory end-point: Osimertinib and AZ5104 concentrations in cerebrospinal fluid.

    On a voluntary basis, patients may opt to undergo lumbar punctures, to allow for determination of osimertinib and AZ5104 (metabolite) exposure in the brain liquor (cerebrospinal fluid). This will be a purely descriptive analysis. This technique might help to shed light on how well osimertinib and its metabolite is able to reach CNS metastases. Because of the invasive nature of the analysis, lumbar punctures will be considered optional, and not required for trial participation.

    Time frame: 12 weeks after intervention initiation

  5. Cohort 2 exploratory end-point: Liquid biopsy measurements of resistance mutations in cerebrospinal fluid

    On a voluntary basis, patients may opt to undergo lumbar punctures, to allow for determination of tumor-cell genotype and the presence of resistance mutations through liquid biopsy analysis. This will be a purely descriptive analysis. This technique might help to shed light on how resistance develops in CNS metastases. Because of the invasive nature of the analysis, lumbar punctures will be considered optional, and not required for trial participation.

    Time frame: 12 weeks after intervention initiation

07

Study locations

1 of 1 sites recruiting
08

References and documents

Publications

  • van Veelen A, Gulikers J, Hendriks LEL, Dursun S, Ippel J, Smit EF, Dingemans AC, van Geel R, Croes S. Pharmacokinetic boosting of osimertinib with cobicistat in patients with non-small cell lung cancer: The OSIBOOST trial. Lung Cancer. 2022 Sep;171:97-102. doi: 10.1016/j.lungcan.2022.07.012. Epub 2022 Jul 25. PubMed 35933915 ↗
  • Soria JC, Ohe Y, Vansteenkiste J, Reungwetwattana T, Chewaskulyong B, Lee KH, Dechaphunkul A, Imamura F, Nogami N, Kurata T, Okamoto I, Zhou C, Cho BC, Cheng Y, Cho EK, Voon PJ, Planchard D, Su WC, Gray JE, Lee SM, Hodge R, Marotti M, Rukazenkov Y, Ramalingam SS; FLAURA Investigators. Osimertinib in Untreated EGFR-Mutated Advanced Non-Small-Cell Lung Cancer. N Engl J Med. 2018 Jan 11;378(2):113-125. doi: 10.1056/NEJMoa1713137. Epub 2017 Nov 18. PubMed 29151359 ↗

Individual participant data

Plan to share: No

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedDate before it movedWhere the date was before it movedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Apr 2024 (actual). Primary completion is estimated for Jul 2027, 39 months after the start.

Of 43 phase 4 interventional studies under Carcinoma, Non-Small-Cell Lung, half reached primary completion within 35 months of starting (the median), counting those still running; a quarter within 22 and three quarters within 48. This study's planned 39 months is above that.

Since we started tracking on Sep 25, 2026, the dates moved once, on Nov 13, 2026: primary completion Jun 2026 → Jul 2027 and completion Sep 2026 → Sep 2027.

Earlier changes are on the record history on ClinicalTrials.gov ↗

How these figures are worked out, and which studies are left out of them.

Registered
Feb 2, 2023
First posted
Feb 28, 2023
StartActual
Apr 1, 2024
Primary completionEst.
Jul 1, 2027was Jun 2026
CompletionEst.
Sep 1, 2027was Sep 2026
Last update
Nov 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Primary completion
Jun 1, 2026→Jul 1, 2027
Nov 13, 2026
Study completion
Sep 1, 2026→Sep 1, 2027
Nov 13, 2026
Show all 1 update
  1. Nov 13, 2026
    Primary completion Jun 1, 2026→Jul 1, 2027
    Study completion Sep 1, 2026→Sep 1, 2027
    + 3 other changes: identifiers, verification date and responsible party

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT05748093
Collaborators
Erasmus Medical Center, Antoni van Leeuwenhoek Hospital, University Medical Center Groningen, Zuyderland Medisch Centrum
Responsible party
Sponsor
First posted
Feb 28, 2023
Start date
Apr 1, 2024
Primary completion
Jul 1, 2027 (estimated)
Completion
Sep 1, 2027 (estimated)
Last update
Nov 13, 2026

Study contacts

Paul Kruithof, PharmD, MSc
Contact
paul.kruithof@mumc.nl
+31433871881
Sander Croes, PharmD, PhD
Contact
s.croes@mumc.nl
+31433871881
Lizza Hendriks, MD, PhD
principal investigator · Maastricht University Medical Centre+

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Cobicistat · Osimertinib

Start the discussion